Vevye

Phase 3Small molecule

Roche

Vevye is one of 12 small molecule programs targeting Dry Eye. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dry EyeNot yet recruiting

Meibomian Gland DysfunctionNot yet recruiting

Dry EyePhase 3

Not yet recruiting

Meibomian Gland DysfunctionPhase 3

Not yet recruiting

Competition

Competitive Landscape

10 competitors in Dry Eye

#DrugCompanyPhaseTrials

Neoral

Novartis

Phase 3

1 2

HUMULIN R

Eli Lilly

Approved

1 3

Treatment

GSK

Phase 3

1 4

Vevye

Roche

Phase 3

1 5

Accutane

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Diquafosol Tetrasodium

Merck & Co.

Preclinical

1 7

SYSTANE ULTRA Lubricant Eye

AAlcon Research

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalNot yet recruiting

Meibomian Gland Dysfunction

NCT07224529

Q2 2027

Post-ApprovalNot yet recruiting

Dry Eye

NCT07368595

Clinical

Trials by Indication[1]

Meibomian Gland Dysfunction1 trial

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

Not yet recruiting·UUniversity of Alabama at Birmingham·Phase 4·NCT07224529·48 enrolled

Dry Eye1 trial

Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks

Not yet recruiting·—·Phase 4·NCT07368595·60 enrolled

Dry Eye Disease1 trial

A Longitudinal, Open-label, Multi-center Study to Explore the Relationship Between Signs, Symptoms, Molecular and Imaging Biomarkers in Participants With Dry Eye Disease Following Anti-inflammatory Treatment

Completed· Roche logo

Roche·Approved·NCT07025811·378 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Vevye. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vevye compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vevye. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Roche

Vevye

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Meibomian Gland Dysfunction1 trial

Dry Eye1 trial

Dry Eye Disease1 trial

References

Drug Info

Quick Facts

Related News